Warfarin-antiretroviral interactions

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 322-328

  Liedtke, Michelle D ^a   Rathbun, R Chris ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiretrovirals; Drug interactions; Nonnucleoside reverse transcriptase inhibitor; Protease inhibitor; Warfarin

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 2C9; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; WARFARIN; ZIDOVUDINE;

ANTIVIRAL THERAPY; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SYSTEMATIC REVIEW;

ANTI-RETROVIRAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; WARFARIN;

EID: 60349110009     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L497     Document Type: Review

References (44)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9. DOI 10.1016/S0140-6736(08)61113-7
2. Pallela FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Aquir Immune Defic Syndr 2006;43:27-34. DOI 10.1097/01.qai.0000233310.90484.16
3. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27. DOI 10.1086/378131
4. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008;133(6 suppl):71S-198S. DOI 10.1378/chest.08-0693
5. Dionisio D, Mininni S, Bartolozzi D, Esperti F, Vivarelli A, Leoncini F. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001;15:277-8. DOI 10.1097/00002030-200101260-00021
6. Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008;28:945-9. DOI 10.1592/phco.28.7.945
7. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-7. DOI 10.1086/524086
8. Gatti G, Alessandrini A, Camera M, Di Biagio A, Bassetti M, Rizzo F. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-6.
9. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-302. DOI 10.1345/aph.17456
10. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-9. DOI 10.1503/cmaj.061284
11. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999; 13:1788-9. DOI 10.1097/00002030-199909100-00028
12. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir (letter). Ann Pharmacother 1997;31:647.
13. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.
14. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-30.
15. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-9. DOI 10.1021/tx00025a009
16. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74. DOI 10.1016/s0163-7258(96)00140-4
17. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
18. von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85-91.
19. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-9. Epub 2007 Jul 16. DOI 10.1124/dmd.107.016089
20. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
21. Product information. Selzentry (maraviroc). New York, NY: Pfizer Labs, August 2007.
22. Tseng A, Chionglo M. Selected properties of maraviroc. www/tthhivcinic.com/pdf/CCR5%20maraviroc.pdf (accessed 2008 Jul 31).
23. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16:101-10.
24. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79:291-302. DOI 10.1016/j.clpt.2005.11.011
25. Human Cytochrome P450 Allele Nomenclature Committee. www.cypalleles.ki. se/cyp2c9.htm (accessed 2008 Jul 18).
26. Ma Q, Okusanya O, Smith P, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005;1:473-85. DOI 10.1517/17425255.1.3.473
27. Product information. Intelence (etravirine). Raritan, NJ: Tibotec Therapeutics, January 2008.
28. Product information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, August 2007.
29. Product information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, November 2007.
30. Product information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, May 2007.
31. Product information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, February 2008.
32. Shelton M, Cloen D, Becker M, Hsyu P, Wilton J, Hewitt R. Evaluation of the pharmacokinetic interactions between phenytoin and nelfinavir in healthy volunteers at steady state (abstract 426). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000.
33. Honda M, Yasuoka A, Aoki M, Oka S. A generalized seizure following initiation of neifinavir in a patient with human immunodeficiency virus type I infection, suspected due to interaction between neifinavir and phenytoin. Intern Med 1999;38:302-3. DOI 10.2169/internalmedicine.38.302
34. Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail study to investigate the in-vivo drug interaction potential of darunavir coadministered with low-dose ritonavir (DRV/r; RTV) on cytochrome P450 enzymes 2D6, 2C9 and 2C19. Presented at: 9th International Workshop on Clinical Pharmacology of HIV, 2008.
35. Product information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, June 2008.
36. Tipranavir. Antiviral Drugs Advisory Committee (AVDAC) briefing document, NDA 21-814. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2005.
37. Product information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, March 2008.
38. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423-31.
39. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4. DOI 10.1046/j.1365-2125.1997.006
40. Product information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories Inc., July 2007.
41. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007;27:888-909. DOI 10.1592/phco.27.6.888
42. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2008 Jul 3).
43. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905.
44. King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004;43:293-310.